Latest news with #SLL
India Today
2 days ago
- Entertainment
- India Today
Exclusive: Good Boy's Park Bo-gum, Lee Sang-yi are ready for India, Bollywood
The excitement surrounding 'Good Boy' is sky-high, and at the heart of it lies a story that's as emotionally resonant as it is action-packed. Produced by SLL, th K-drama premiered on Prime Video and follows a group of former athletes who are recruited into law enforcement given their this exclusive conversation with India Today, the star cast—Park Bo-gum, Kim So-hyun, Lee Sang-yi, Heo Seong-tae, and Tae Won-seok opened up about what makes the drama special, their personal strengths as actors, and why a visit to India might be on the cards sooner than we is no secret that each actor brings a distinctive energy to their role in 'Good Boy', be it Bo-gum or Sang-Yi. When asked about their individual strengths, they offered candid, thoughtful insights. Park Bo-gum, who plays a boxing medallist, noted, 'Personally in the story, my character is the one in charge of fist fights. I think as an actor, what I am good at is having that active energy, being action-first, and being very agile, I would say that's one of my strengths.' Park Bo-gum: Photo credit: Prime Video, SLL For Kim So-hyun, it's her calm intensity that mirrors her character: 'The way her nature is very calm and grounded, and she's also very well-adjusted, and has a sense of boldness that comes from being calm. I think that's something that I share on a personal level as well." Kim So-kyun in a still from Good Boy'. Photo credit: Prime Video, SLL advertisementActor Lee Sang-yi, who was last seen in 'Spice Up Our Love', shared, 'When it comes to creating harmony and continuity between scenes, I like paying attention to that. I think it was similar for me as an actor and for my character."Heo Sung-tae, the charm machine, laughed, 'My character Man-sik is in charge of the beauty and the humour of the series. Look out for a lot of improvised scenes by me!' Tae Won-seok added with a grin, 'My character is adorable but strong—and I'm pretty strong in real life too.'Meanwhile, Bo-gum, who was last seen in the popular K-drama 'When Life Gives You Tangerines', may have fewer projects lined up, but his approach is anything but random. 'The first thing I look for is whether the script is entertaining to read,' he explained. 'Would I recommend this to someone? Would it make you think, talk about it with family? That's what matters.'As global demand for K-dramas grows, he adds, 'I know there are fans who study Korean and are curious about Korea through these shows. So, I'm more cautious about the dramas I choose to be part of.' India is perhaps one of the top nations that's quite vocal about their love for K-drama. The Hallyu wave here is real. When asked if the cast had any plans to visit India or participate in an Indian film, the answer was a resounding lit up at the mention of Indian dance and music: 'I love dancing and music. I'm going to go there.' Won-seok, with a smile, added, 'I lift my mood with Indian curry. I'd love to taste the original.'Bo-gum chimed in, 'India isn't just about great food. It has so much to offer. If given the chance, I'd love to travel there." He continued, "Hopefully, maybe all of us, the 'Good Boy' team, can star in an Indian musical film altogether."He ended on a heartfelt note: 'What's also really amazing is we didn't have a lot of chances to speak to or meet with Indian fans or the Indian media. And so, to be able to do something like this because you showed so much love for K-dramas, we are very grateful. It's a huge honour, and I feel very blessed."New episodes of Good Boy' drop every Friday on Prime Video. You May Also Like
Medscape
16-05-2025
- Health
- Medscape
7 T MRI Matches 3 T for Diagnosing Wrist Ligament Injuries
MRI at 7 tesla (T) and 3 T field strengths showed similar accuracy in detecting triangular fibrocartilage complex (TFCC) and scapholunate ligament (SLL) injuries, according to a new study. Although some injuries were missed, MRI identified additional pathologies not seen on arthroscopy, supporting its complementary role in diagnosis. METHODOLOGY: This prospective study (May 2020 to April 2024) included 24 patients with a suspected TFCC or SLL injury (median age, 34 years; 29.2% women) who underwent both 7 T and 3 T MRI examinations followed by arthroscopy. Four musculoskeletal radiologists independently evaluated MRI examinations in a randomised order, comparing findings to wrist arthroscopy results. Sensitivity, specificity, area under the curve (AUC), and other parameters were estimated for each MRI field strength. TAKEAWAY: For TFCC injuries, 7 T MRI had a sensitivity of 0.85, specificity of 0.68, and AUC of 0.82, whereas 3 T MRI had a sensitivity of 0.75, specificity of 0.73, and AUC of 0.77. For SLL injuries, 7 T MRI had a sensitivity of 0.70, specificity of 0.65, and AUC of 0.74, whereas 3 T MRI had a sensitivity of 0.69, specificity of 0.55, and AUC of 0.70. For both TFCC and SLL injuries, no statistically significant difference was found between 7 T and 3 T MRI compared with arthroscopy. In 58% of patients, MRI identified additional pathologies including tendon injuries and ganglia, which were essential for a complete diagnosis. IN PRACTICE: "Neither MRI at 7 T nor 3 T can replace wrist arthroscopy, but MRI is an important complementary tool in the diagnostic workup of suspected wrist ligament injuries, with the ability to diagnose additional types of pathologies not accessible with arthroscopy," the authors wrote. SOURCE: This study was led by Simon Götestrand, Lund University, Lund, Sweden. It was published online on May 08, 2025, in European Radiology . LIMITATIONS: This study was limited by a likely selection bias as all patients were scheduled for arthroscopy, increasing the probability of injury. The small sample size also limited the statistical power. DISCLOSURES: Open access funding was provided by Lund University. The authors reported having no conflicts of interest.
Business Recorder
15-05-2025
- Business
- Business Recorder
SME Leasing Limited board approves closure plan
The Board of Directors of SME Bank Limited has approved the closure strategy of the company, according to a stock notice on Thursday. The company shared the development in a notice to the Pakistan Stock Exchange (PSX). 'The Board of Directors of SME Leasing Limited has approved the Winding Down Plan, of the company. 'The Board of Directors of SME Bank Limited (the parent company) has also approved the SLL's Winding Down Plan in its meeting held on May 06, SME Bank Limited has also written a letter dated May L3, 2025 to Securities and Exchange Commission of Pakistan in this respect and has requested to defer the proceedings initiated for order of winding up of the SME Leasing Limited,' the notice read. The Winding Down Plan envisages as under: To close the branches, laying off employees, shifting of Head Office premises, disposal/ sale of immoveable properties of the company etc. To sale / disposal of leased portfolio to another operating leasing company. To sell the SME Leasing Limited with an anticipation that it would yield better sale price in short time than liquidation process. According to the information available to the company's website, SME Leasing Limited was incorporated in Pakistan in July 2002 and acquired the status of listed company in December 2006. SLL is a subsidiary of SME Bank Limited which holds 73.14% of the company's shares. The company is licensed to carry out leasing business as a Non Banking Finance Company (MBFC) under the Non-Banking Finance Companies Rules issued by the Securities and Exchange Commission of Pakistan.
Yahoo
12-05-2025
- Business
- Yahoo
InnoCare's Mesutoclax Receives Breakthrough Therapy Designation from China's NMPA
BEIJING, May 12, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its B-cell lymphoma-2 (BCL2) inhibitor, Mesutoclax (ICP-248), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China! Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor, developed as monotherapy or in combination with orelabrutinib for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and other non-Hodgkin's lymphomas (NHLs), and as well as acute myeloid leukemia (AML). BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, "We are delighted that mesutoclax has been granted Breakthrough Therapy Designation, which will help expedite multi-center, multi-indication clinical trials for mesutoclax in China and globally to benefit patients as early as possible." Clinical trials of mesutoclax are ongoing both in China and globally, including a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of CLL/SLL patients, as well as a clinical trial of mesutoclax for the treatment of AML. The Breakthrough Therapy Designation (BTD) by the CDE aims to accelerate the clinical development of new drugs that demonstrate significant clinical advantages. New drugs granted BTD are typically intended for diseases that are life-threatening or severely impair quality of life, and have demonstrated clear advantages in efficacy or safety during clinical trials. About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View source version on Contacts Media Chunhua Investors 86-10-66609999ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
12-05-2025
- Business
- Business Wire
InnoCare's Mesutoclax Receives Breakthrough Therapy Designation from China's NMPA
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its B-cell lymphoma-2 (BCL2) inhibitor, Mesutoclax (ICP-248), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China! This marks the first BCL2 inhibitor to receive BTD recognition in China! Clinical trials of mesutoclax are ongoing both in China and globally, including a Phase III registrational trial for CLL/SLL and a clinical trial for AML. Share Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor, developed as monotherapy or in combination with orelabrutinib for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and other non-Hodgkin's lymphomas (NHLs), and as well as acute myeloid leukemia (AML). BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, 'We are delighted that mesutoclax has been granted Breakthrough Therapy Designation, which will help expedite multi-center, multi-indication clinical trials for mesutoclax in China and globally to benefit patients as early as possible.' Clinical trials of mesutoclax are ongoing both in China and globally, including a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of CLL/SLL patients, as well as a clinical trial of mesutoclax for the treatment of AML. The Breakthrough Therapy Designation (BTD) by the CDE aims to accelerate the clinical development of new drugs that demonstrate significant clinical advantages. New drugs granted BTD are typically intended for diseases that are life-threatening or severely impair quality of life, and have demonstrated clear advantages in efficacy or safety during clinical trials. About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
